| Field | Specification |
|---|---|
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of 6-keto-PGF1a concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Universal 6-keto-PGF1a. During the reaction, Universal 6-keto-PGF1a in the sample or standard competes with a fixed amount of Universal 6-keto-PGF1a on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Universal 6-keto-PGF1a. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Universal 6-keto-PGF1a in tested samples can be calculated by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 9.38 pg/mL |
|---|---|
| Detection Range | 15.63-1000 pg/mL |
| Total Assay Time | 2 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Universal (multi-species validated) |
| Detection Method | Competitive |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Universal 6-keto-PGF1a in samples.No significant cross-reactivity or interference between Universal 6-keto-PGF1a and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 9.38 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 2 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Competitive ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant 6-keto-PGF1a standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Temporal inhibition of mouse mammary gland cancer metastasis by CORM-A1 and DETA/NO combination therapy (2019) Theranostics. 10.7150/thno.31461
Selective binding of cationic fibrinogen-mimicking chitosan nanoparticles to activated platelets and efficient drug release for antithrombotic therapy (2024) INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 10.1016/j.ijbiomac.2024.131742
Quince extract resists atherosclerosis in rats by down-regulating the EGFR/PI3K/Akt/GSK-3β pathway (2023) BIOMEDICINE & PHARMACOTHERAPY. 10.1016/j.biopha.2023.114330
Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways (2022) Frontiers in Pharmacology. 10.3389/fphar.2022.1018438
Anti-platelet aggregation of Panax notoginseng triol saponins by regulating GP1BA for ischemic stroke therapy (2021) Chinese Medicine. 10.1186/s13020-021-00424-3
An-Gong-Niu-Huang-Wan (AGNHW) regulates cerebral blood flow by improving hypoperfusion, cerebrovascular reactivity and microcirculation disturbances after stroke (2024) Chinese Medicine. 10.1186/s13020-024-00945-7
Mailuoning oral liquid ameliorates vasculitis in thromboangiitis obliterans rats via inactivating cGAS-STING-IRF3 and TLR4-MAPKs/NF-κB signaling pathways (2024) JOURNAL OF ETHNOPHARMACOLOGY. 10.1016/j.jep.2024.118707
Carthamus tinctorius L. protects cerebral ischemia/reperfusion injury via arachidonic acid/p53-mediated apoptosis axis (2024) Frontiers in Pharmacology. 10.3389/fphar.2024.1504109
Nicotinic acetylcholine receptor-mediated effects of varenicline on LPS-elevated prostaglandin and cyclooxygenase levels in RAW 264.7 macrophages (2024) Frontiers in Molecular Biosciences. 10.3389/fmolb.2024.1392689
Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages (2025) NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 10.1007/s00210-025-04225-5
Extract from Rostellularia procumbens (L.) Nees Inhibits Thrombosis and Platelet Aggregation by Regulating Integrin β3 and MAPK Pathways (2020) ACS Omega. 10.1021/acsomega.0c05227
The Anti-Inflammatory Effect of Smilax china L. Extract on LPS-Stimulated THP-1 via Downregulation of MAPK and NF- κ B Signaling Pathway (2021) Evidence-based Complementary and Alternative Medicine. 10.1155/2021/9958808
Peroxisome proliferator?activated receptor γ alleviates human umbilical vein endothelial cell injury in deep vein thrombosis by blocking endoplasmic reticulum stress (2024) Experimental and Therapeutic Medicine. 10.3892/etm.2024.12674
